[go: up one dir, main page]

EP1696889A1 - Pharmaceutical compositions of benzimidazole and processes for their preparation - Google Patents

Pharmaceutical compositions of benzimidazole and processes for their preparation

Info

Publication number
EP1696889A1
EP1696889A1 EP04769201A EP04769201A EP1696889A1 EP 1696889 A1 EP1696889 A1 EP 1696889A1 EP 04769201 A EP04769201 A EP 04769201A EP 04769201 A EP04769201 A EP 04769201A EP 1696889 A1 EP1696889 A1 EP 1696889A1
Authority
EP
European Patent Office
Prior art keywords
pharmaceutical composition
composition according
benzimidazole derivative
coat layer
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04769201A
Other languages
German (de)
French (fr)
Inventor
Romi Barat Singh
Pananchukunnath Manoj Kumar
Vishnubhotla Nagaprasad
Sanjeev Kumar Sethi
Rajiv Malik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ranbaxy Laboratories Ltd
Original Assignee
Ranbaxy Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IB2004/000536 external-priority patent/WO2004075881A1/en
Application filed by Ranbaxy Laboratories Ltd filed Critical Ranbaxy Laboratories Ltd
Publication of EP1696889A1 publication Critical patent/EP1696889A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer

Definitions

  • the technical field of the present invention relates to stable pharmaceutical compositions of acid-labile benzimidazole derivative using increased amounts of low- viscosity hydroxypropylcellulose, and processes for the preparation of these compositions.
  • Benzimidazole derivatives such as esomeprazole, omeprazole, lansoprazole, leminoprazole, pariprazole, rabeprazole and pantoprazole, etc. are known proton pump inhibitors with powerful inhibitory action against the secretion of gastric acid.
  • enteric coatings are either themselves acidic materials, or contain acidic materials, • which may react with the benzimidazole derivative and cause degradation.
  • conventional enteric coatings are not suitable for this purpose.
  • U.S. Patent No. 4,786,505 addresses this problem by formulating the benzimidazole derivative and an alkaline reacting compound into pellets with an inert sub-coating and then an enteric coating.
  • the alkaline reacting compound presumably increases stability by maintaining the benzimidazole in an alkaline environment and the inert sub-coating prevents contact between the benzimidazole derivative and the enteric coating.
  • U.S. Patent Application No. 2002/0039597 discloses a pharmaceutical preparation of a benzimidazole type compound that is characterized within the application as being chemically stable.
  • the preparation is stabilized by incorporating in the core at least one substance selected from sodium carbonate, potassium carbonate, sodium hydroxide, potassium hydroxide, amino alkyl methacrylate copolymer E, arginine aspartate, hydroxypropylcellulose and crospovidone.
  • Summary of the Invention In one general aspect there is provided a pharmaceutical composition that includes one or more cores.
  • the cores include an acid-labile benzimidazole derivative and at least 10% w/w of low- viscosity hydroxypropylcellulose by weight of the benzimidazole derivative.
  • Embodiments of the pharmaceutical composition may include one or more of the following features.
  • the pharmaceutical composition may be a solid dosage form selected from the group that includes powder, tablet, granule, pellet, spheroid and capsule.
  • the low- viscosity hydroxypropylcellulose may vary from about 10% to about 100% by weight of the weight of the benzimidazole derivative.
  • the low- viscosity hydroxypropylcellulose may be a hydroxypropylcellulose having a viscosity less than about 1000 cps.
  • the benzimidazole derivative may be one or more selected from the group that includes esomeprazole, omeprazole, lansoprazole, leminoprazole, pariprazole, rabeprazole, pantoprazole, and their pharmaceutically acceptable salts with metals.
  • the benzimidazole derivative may be one or both of pantoprazole sodium and rabeprazole sodium.
  • the pharmaceutical composition may further include one or more pharmaceutically acceptable inert excipients.
  • the one or more pharmaceutically acceptable inert excipients may be selected from the group that includes alkaline reacting compounds, antioxidants, binders, diluents, disintegrants, surfactants,- plasticizers, coloring agents and flavoring agents.
  • the alkaline reacting compound may be one or more of sodium, potassium, calcium, magnesium, and aluminum salts of phosphoric acid, carbonic acid, citric acid or other weak inorganic or organic acids, aluminum hydroxides, calcium hydroxides and magnesium hydroxides, magnesium oxide, Ai 2 O 3 .6MgO.CO .12H 2 O, (Mg 6 Al 2 (OH)16CO 3 .4H 2 O), MgO.Al 2 O 3 .2SiO 2 .nH 2 O, organic pH buffering substances, and trihydroxymethylaminomethane.
  • the alkaline reacting compound may be sodium carbonate.
  • the pharmaceutical composition may further include one or both of a sub-coat layer and an enteric coat layer around the core.
  • the sub coat layer may be one or more film-forming agents.
  • the film-forming agent may be selected from the group that includes carageenan, ethylcellulose, hydroxypropyl methylcellulose, hydroxypropyl cellulose, methylcellulose, carboxymethylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, polyethylene glycol, polyvinyl alcohol and xanthan gum.
  • the film-forming agent may be hydroxypropyl methylcellulose.
  • the enteric coat layer may be one or more enteric polymers.
  • the enteric polymer may be one or more of cellulose acetate phthalate, hydroxypropyl methylcellulose acetate phthalate, polyvinyl acetate phthalate, hydroxy propyl phthalate, hydroxypropyl methylcellulose phthalate hydroxypropyl methylcellulose acetate succinate; and methacrylic acid copolymers.
  • the enteric polymer may be methacrylic acid copolymer.
  • a process for the preparation of a pharmaceutical composition that contains one or more cores. The process includes forming a core containing an acid-labile benzimidazole derivative and at least 10% w/w of low- viscosity hydroxypropylcellulose by weight of the benzimidazole derivative.
  • Embodiments of the process may include one or more of the following features or those described above.
  • the acid-labile benzimidazole may be blended with the low- viscosity hydroxypropylcellulose with or without one or more pharmaceutically acceptable inert excipients and then formed into the core.
  • the process may further include forming tablets from the cores.
  • the blend may be granulated and the granulation may be carried out by wet granulation or dry granulation technique.
  • the blend may be further processed into a suitable sized core by the process of extrusion-spheronization.
  • the process may further include coating the core with one or both of a sub coat layer and an enteric coat layer.
  • Either or both of the sub coat layer and the enteric coat layer may be applied as a solution or dispersion of film-forming agent or enteric polymer in a suitable solvent.
  • the solvent may be selected from the group that includes methylene chloride, isopropyl alcohol, acetone, methanol, ethanol and water.
  • Either or both of the sub coat layer and the enteric coat layer may be applied using a hot melt technique.
  • the method includes administering a pharmaceutical composition of benzimidazole derivative that includes one or more cores containing an acid labile benzimidazole derivatives and at least 10% w/w of low- viscosity hydroxypropylcellulose by weight of the benzimidazole.
  • the method of treating may include one or more of the following features or those described above.
  • the benzimidazole derivative may be selected from the group that includes esomeprazole, omeprazole, lansoprazole, leminoprazole, pariprazole, rabeprazole, pantoprazole; and their pharmaceutically acceptable salts.
  • the acceptable salt may be one or more of sodium, potassium, calcium, and magnesium.
  • the benzimidazole derivative may be one or both of pantoprazole sodium and rabeprazole sodium.
  • the details of one or more embodiments of the inventions are set forth in the description below. Other features, objects and advantages of the inventions will be apparent from the description and claims. Detailed Description of the Invention As may be evident from the discussion of the background above, stabilization of benzimidazole derivatives in pharmaceutical compositions has been a key area of research ever since the discovery of these benzimidazoles as potent proton pump inhibitors.
  • benzimidazole derivatives as used herein includes benzimidazole derivatives that are used as proton pump inhibitors. Examples include esomeprazole, omeprazole, lansoprazole, leminoprazole, pariprazole, rabeprazole, pantoprazole; and pharmaceutically acceptable salts thereof.
  • Pharmaceutically acceptable salts include metal salts of sodium, potassium, calcium, magnesium and the like.
  • pantoprazole sodium or rabeprazole sodium may be used.
  • Low- iscosity hydroxypropylcellulose is conventionally used as a binder, although in low amounts.
  • the pharmaceutical compositions of the present invention comprise increased or high amounts of low- viscosity hydroxypropylcellulose, at least in amounts greater than as a conventional binder.
  • We have surprisingly discovered that the chemical degradation, as well as the discoloration, of highly acid- labile benzimidazole derivatives, particularly pantoprazole and rabeprazole may be inhibited or at least reduced to a reasonable extent with the use of higher amounts of low- viscosity hydroxypropylcellulose.
  • the amount of low- viscosity hydroxypropylcellulose should be at least about 10% by weight of the weight of benzimidazole derivative, and in particular from about 10% to about 100% of the weight of the benzimidazole derivative.
  • pharmaceutical compositions comprising pantoprazole and higher amounts of low- viscosity hydroxypropylcellulose were prepared and evaluated for stability at 400°C and 75 % relative humidity over a period of 3 months.
  • the results of the stability evaluation, listed in Table 1 below are highly convincing for recommending the use of low- viscosity hydroxypropylcellulose as a stabilizer.
  • the results in Table 1 further reveal the synergistic improvement in stability upon incorporation of alkaline reacting compounds.
  • Hydroxypropylcellulose is a non-ionic water-soluble cellulose ether that is formed by reaction with propylene oxide. It has a longstanding history of safe and effective use in the pharmaceutical industry. Hydroxypropylcellulose is commercially available from Aqualon and Nippon Soda Co. under the brand names Klucel® and HPC® and provides a remarkable set of physical properties for tablet binding, modified release, and film coating. Based on the requirement and the role it has to play in the pharmaceutical composition, hydroxypropylcellulose of a desired viscosity range may be selected. Broadly, the viscosity ranges and corresponding hydroxylpropylcelluloses are classified as low, medium and high viscosity hydroxypropylcelluloses.
  • low-viscosity hydroxypropylcellulose examples include Klucel EF, Klucel LF, Klucel JF and Klucel GF, whose 2% by weight aqueous solutions have viscosities less than about 1000 cPs.
  • Other examples are HPC-SL, HPC-L, and HPC-M whose 2% by weight aqueous solutions have viscosities of 3-6, 6-10, and 150-400 cPs, respectively.
  • HPC-L may be used.
  • pharmaceutical composition as used herein includes solid dosage forms such as powder, tablet, granule, pellet, spheroid, capsule, and the like.
  • the pharmaceutical composition may include one or more of a core, a sub coat layer, an enteric coat layer, and one or more pharmaceutically acceptable inert excipients.
  • the term "core” as used herein includes conventionally used cores for oral administration such as tablets, granules, pellets, spheroids, capsules and the like.
  • the core may comprise acid-labile benzimidazole derivative and low- viscosity hydroxypropylcellulose with or without other pharmaceutically acceptable inert excipients.
  • the sub coat layer may comprise a film-forming agent with or without other pharmaceutically acceptable inert excipients.
  • film forming agents include carageenan, hydroxypropyl methylcellulose, hydroxypropylcellulose, methylcellulose, carboxymethylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, polyethylene glycol, polyvinyl alcohol, xanthan gum and the like.
  • hydroxypropylmethyl cellulose may be used as the film forming agent in concentrations from about 40% to about 90% by weight of the total solid content in the coating composition.
  • Sub coating is carried out until a weight build-up is attained of about 7.5% to about 20% w/w over the core, in particular about 10% to about 20% w/w.
  • the enteric coat layer may comprise an enteric polymer with or without other pharmaceutically acceptable inert excipients.
  • enteric polymers include cellulose acetate phthalate, hydroxypropyl methylcellulose acetate phthalate, polyvinyl acetate phthalate, hydroxy propyl phthalate, hydroxypropyl methylcellulose phthalate (HPMC phthalate), hydroxypropyl methylcellulose acetate succinate; methacrylic acid copolymers such as Eudragit ® L 100-55, Eudragit ® L30 D-55, Eudragit ® L 100, Eudragit ® S 100; and mixtures thereof.
  • methacrylic acid copolymers for example, Eudragit ® L30 D-55 & Eudragit ® L 100 maybe used as the enteric polymer in concentrations from about 40% to about 95% by weight of the total solid content in the coating composition. Enteric coating is carried out until attaining a weight build up of about 7.5% to about 15 % w/w over the sub coated core, in particular about 10% to about 12.5% w/w.
  • pharmaceutically acceptable inert excipients as used herein includes all physiologically inert excipients used in the pharmaceutical art of dispensing.
  • alkaline reacting compounds examples include sodium, potassium, calcium, magnesium, and aluminum salts of phosphoric acid, carbonic acid, citric acid or other suitable wealc inorganic or organic acids, such as sodium carbonate; substances normally used in antacid preparations such as aluminum, calcium and magnesium hydroxides; magnesium oxide or composite substances such as Al 2 O 3 .6MgO.C ⁇ 2 .12H 2 ⁇ , (Mg 6 Al 2 (OH) ⁇ 6 CO 3 .4H 2 O), MgO.Al 2 O 3 .2SiO 2 .nH 2 O or similar compounds; organic pH buffering substances such as trihydroxymethylaminomethane and the like.
  • antioxidants examples include lipophillic antioxidants, inorganic antioxidants and the like.
  • BHA butylated hydroxy anisole
  • BHT butylated hydroxy toluene
  • binders include methyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, polyvinylpyrrolidone, gelatin, gum arabic, ethyl cellulose, polyvinyl alcohol, pullulan, pregelatinized starch, agar, tragacanth, sodium alginate, propylene glycol, and the like.
  • diluents include calcium carbonate, calcium phosphate- dibasic, calcium phosphate-tribasic, calcium sulfate, cellulose-microcrystalline, cellulose powdered, dextrates, dextrins, dextrose excipients, fructose, kaolin, lactitol, lactose, mannitol, sofbitol, starch, starch pregelatinized, sucrose, sugar compressible, sugar confectioners, and the like.
  • disintegrants include low-substituted hydroxypropylcellulose L-HPC), sodium starch glycollate, carboxymethyl cellulose, calcium carboxymethyl cellulose, sodium carboxymethyl cellulose, croscarmellose sodium A-type (Ac-di-sol), starch, crystalline cellulose, hydroxypropyl starch, partly pregelatinized starch, and the like.
  • surfactants include both non-ionic and ionic (cationic, anionic and zwitterionic) surfactants suitable for use in pharmaceutical compositions.
  • polyethoxylated fatty acids and their derivatives for example polyethylene glycol 400 distearate, polyethylene glycol - 20 dioleate, polyethylene glycol 4 -150 mono dilaurate, polyethylene glycol -20 glyceryl stearate; alcohol - oil transesterification products, for example polyethylene glycol - 6 corn oil; polyglycerized fatty acids, for example polyglyceryl — 6 pentaoleate; propylene glycol fatty acid esters, for example propylene glycol monocaprylate; mono and diglycerides for example glyceryl ricinoleate; sterol and sterol derivatives; sorbitan fatty acid esters and its derivatives, for example polyethylene glycol - 20 sorbitan monooleate, sorbitan monolaurate; polyethylene glycol alkyl ether or phenols, for example polyethylene glycol - 20 cetyl ether, polyethylene glycol - 10 - 100 nonyl
  • Coloring agents and flavoring agents include any FDA approved color or flavor for oral use.
  • Stable pharmaceutical compositions of acid- labile benzimidazole derivative may be prepared by processes known in the prior art including, for example, by comminuting, mixing, granulation, melting, sizing, filling, drying, molding, immersing, coating, compressing, extrusion-spheronization etc.
  • a core that includes an acid-labile benzimidazole derivative is prepared by a process that includes the steps of blending benzimidazole derivative and low-viscosity hydroxypropylcellulose with or without one or more pharmaceutically acceptable inert excipients; wet granulating the blend with a granulating fluid or solution/dispersion of one or more pharmaceutically acceptable inert excipients in the granulating fluid; drying and sizing the granules; optionally blending with one or more pharmaceutically acceptable inert excipient; and forming a suitable sized core.
  • a core that includes an acid-labile benzimidazole derivative is prepared by a process that includes the steps of blending benzimidazole derivative and low-viscosity hydroxypropylcellulose with or without one or more pharmaceutically acceptable inert excipients; dry granulating the blend by roller compactor or slugging; sizing the granules; optionally blending with one or more pharmaceutically acceptable inert excipients; and forming a suitable sized core.
  • a core that includes an acid-labile benzimidazole derivative is prepared by a process that includes the steps of blending benzimidazole derivative and low-viscosity hydroxypropylcellulose with or without one or more pharmaceutically acceptable inert excipients; and forming a suitable sized core.
  • a core that includes an acid-labile benzimidazole derivative is prepared by a process that includes the steps of blending benzimidazole derivative and low- viscosity hydroxypropylcellulose with or without one or more pharmaceutically acceptable inert excipients; forming a wet mass using a granulating fluid or solution/dispersion of one or more pharmaceutically acceptable inert excipients in the granulating fluid; passing the wet mass through an extruder equipped with a screen; spheronizing the extrudate in a spheronizer; drying and sizing the spheroids; and forming a suitable sized core.
  • the sub coat layer and enteric coat layer may be applied over the core prepared by any of the methods above in the form of a solution or dispersion of a film forming agent or an enteric polymer, with or without other pharmaceutically acceptable inert excipients.
  • These coatings may be applied using any conventional coating technique known in the art, including spray coating in a conventional coating pan or fluidized bed processor, or dip coating. Alternatively, either of both of the coatings can be applied using a hot melt technique.
  • Specific examples of solvents used as a granulating fluid and for preparing the solution/dispersion of coating substances include methylene chloride, isopropyl alcohol, acetone, methanol, ethanol, water and the like.
  • the invention is further illustrated by the following examples, which are not intended and should not bee construed to limit the scope of the invention. Examples 1-7 Core tablets
  • a portion of the mannitol, a portion of the microcrystalline cellulose, a portion of the disintegrant (crospovidone or sodium starch glyeollate or L-HPC, etc., respectively) and a portion of the low viscosity hydroxypropylcellulose were mixed with pantoprazole sodium in a high shear blender. This premix was granulated using purified water and the bulk then was dried. The dried granules were sized and mixed with extra granular excipients, which may include the remaining parts of mannitol, microcrystalline cellulose, disintegrant and low-viscosity hydroxypropylcellulose. The blend so obtained then was lubricated with calcium stearate and compressed into suitable sized tablets. The core tablets containing alkaline stabilizer were prepared by incorporating sodium carbonate intra granularly and/or extra granularly. Sub coat Layer
  • Propylene glycol 2.79 Procedure: 1. Propylene glycol and povidone were dissolved in purified water to form a clear solution. 2. Appropriately sieved titanium dioxide and ferric oxide yellow were dispersed in purified water under constant stirring and passed through a colloid mill to form a dispersion. 3. The dispersion of step 2 was added to the solution of step 1. 4. Hydroxypropyl methylcellulose was added to the dispersion of step 3 under stirring for 30 minutes to give a uniform dispersion of 10 - 20 % w/w. 5. The core tablets prepared in the Example 1-7 above then were coated with the dispersion of step 4 until the desired weight build up was attained.
  • the coated tablets were stored at 40 C and 75% relative humidity for 3 months and then the impurities were measured.
  • the results are provided below in Table 1.
  • the results in Table 1 demonstrate that the degradation of benzimidazole derivatives, particularly pantoprazole and rabeprazole, in pharmaceutical compositions can be inhibited by the incorporation of low-viscosity hydroxypropylcellulose at amounts greater than used in the past as a binder in admixture with benzimidazole derivative and therefore support the use of low- viscosity hydroxypropylcellulose as a stabilizer.
  • Table 1 Stability data generated after storage of coated tablets at 40°C, 75% relative humidity for three months

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The technical field of the present invention relates to stable pharmaceutical compositions of acid-labile benzimidazole derivative using increased amounts of low-viscosity hydroxypropylcellulose, and processes for the preparation of these compositions. The pharmaceutical composition includes one or more cores. The cores include an acid-labile benzimidazole derivative and at least 10% w/w of low-viscosity hydroxypropylcellulose by weight of the benzimidazole derivative.

Description

PHARMACEUTICAL COMPOSITIONS OF BENZIMIDAZOLE AND PROCESSES FOR THEIR PREPARATION Technical Field of the Invention The technical field of the present invention relates to stable pharmaceutical compositions of acid-labile benzimidazole derivative using increased amounts of low- viscosity hydroxypropylcellulose, and processes for the preparation of these compositions. Background of the Invention Benzimidazole derivatives, such as esomeprazole, omeprazole, lansoprazole, leminoprazole, pariprazole, rabeprazole and pantoprazole, etc. are known proton pump inhibitors with powerful inhibitory action against the secretion of gastric acid. They are indicated for the treatment of various digestive ulcers, are well known in the art, and are described, for example, in EP 0005129 A (having U.S. equivalent U.S. Patent No. 4,255,431). It has been found, that these benzimidazole derivatives are easily destroyed in acid medium and thus are difficult to formulate for oral administration. Upon oral administration, the pharmaceutical composition comes in contact with the gastric fluid in the stomach, which is highly acidic, leading to breakdown and loss of activity of the benzimidazole derivative. Pharmaceutical compositions comprising acid-labile agents are protected from acidic gastric juices by an enteric coating until it reaches the desired site of action, e.g., the small intestine. Most of the enteric coatings are either themselves acidic materials, or contain acidic materials, •which may react with the benzimidazole derivative and cause degradation. Hence, conventional enteric coatings are not suitable for this purpose. Several approaches have been employed by researches to stabilize acid-labile benzimidazole derivatives in pharmaceutical compositions. For example, U.S. Patent No. 4,786,505 addresses this problem by formulating the benzimidazole derivative and an alkaline reacting compound into pellets with an inert sub-coating and then an enteric coating. The alkaline reacting compound presumably increases stability by maintaining the benzimidazole in an alkaline environment and the inert sub-coating prevents contact between the benzimidazole derivative and the enteric coating. U.S. Patent Application No. 2002/0039597 discloses a pharmaceutical preparation of a benzimidazole type compound that is characterized within the application as being chemically stable. The preparation is stabilized by incorporating in the core at least one substance selected from sodium carbonate, potassium carbonate, sodium hydroxide, potassium hydroxide, amino alkyl methacrylate copolymer E, arginine aspartate, hydroxypropylcellulose and crospovidone. Summary of the Invention In one general aspect there is provided a pharmaceutical composition that includes one or more cores. The cores include an acid-labile benzimidazole derivative and at least 10% w/w of low- viscosity hydroxypropylcellulose by weight of the benzimidazole derivative. Embodiments of the pharmaceutical composition may include one or more of the following features. For example, the pharmaceutical composition may be a solid dosage form selected from the group that includes powder, tablet, granule, pellet, spheroid and capsule. The low- viscosity hydroxypropylcellulose may vary from about 10% to about 100% by weight of the weight of the benzimidazole derivative. The low- viscosity hydroxypropylcellulose may be a hydroxypropylcellulose having a viscosity less than about 1000 cps. The benzimidazole derivative may be one or more selected from the group that includes esomeprazole, omeprazole, lansoprazole, leminoprazole, pariprazole, rabeprazole, pantoprazole, and their pharmaceutically acceptable salts with metals. The benzimidazole derivative may be one or both of pantoprazole sodium and rabeprazole sodium. The pharmaceutical composition may further include one or more pharmaceutically acceptable inert excipients. The one or more pharmaceutically acceptable inert excipients may be selected from the group that includes alkaline reacting compounds, antioxidants, binders, diluents, disintegrants, surfactants,- plasticizers, coloring agents and flavoring agents. The alkaline reacting compound may be one or more of sodium, potassium, calcium, magnesium, and aluminum salts of phosphoric acid, carbonic acid, citric acid or other weak inorganic or organic acids, aluminum hydroxides, calcium hydroxides and magnesium hydroxides, magnesium oxide, Ai2O3.6MgO.CO .12H2O, (Mg6Al2(OH)16CO3.4H2O), MgO.Al2O3.2SiO2.nH2O, organic pH buffering substances, and trihydroxymethylaminomethane. In particular, the alkaline reacting compound may be sodium carbonate. The pharmaceutical composition may further include one or both of a sub-coat layer and an enteric coat layer around the core. The sub coat layer may be one or more film-forming agents. The film-forming agent may be selected from the group that includes carageenan, ethylcellulose, hydroxypropyl methylcellulose, hydroxypropyl cellulose, methylcellulose, carboxymethylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, polyethylene glycol, polyvinyl alcohol and xanthan gum. In particular, the film-forming agent may be hydroxypropyl methylcellulose. The enteric coat layer may be one or more enteric polymers. The enteric polymer may be one or more of cellulose acetate phthalate, hydroxypropyl methylcellulose acetate phthalate, polyvinyl acetate phthalate, hydroxy propyl phthalate, hydroxypropyl methylcellulose phthalate hydroxypropyl methylcellulose acetate succinate; and methacrylic acid copolymers. In particular, the enteric polymer may be methacrylic acid copolymer. In another general aspect there is provided a process for the preparation of a pharmaceutical composition that contains one or more cores. The process includes forming a core containing an acid-labile benzimidazole derivative and at least 10% w/w of low- viscosity hydroxypropylcellulose by weight of the benzimidazole derivative. Embodiments of the process may include one or more of the following features or those described above. For example, the acid-labile benzimidazole may be blended with the low- viscosity hydroxypropylcellulose with or without one or more pharmaceutically acceptable inert excipients and then formed into the core. The process may further include forming tablets from the cores. The blend may be granulated and the granulation may be carried out by wet granulation or dry granulation technique. The blend may be further processed into a suitable sized core by the process of extrusion-spheronization. The process may further include coating the core with one or both of a sub coat layer and an enteric coat layer. Either or both of the sub coat layer and the enteric coat layer may be applied as a solution or dispersion of film-forming agent or enteric polymer in a suitable solvent. The solvent may be selected from the group that includes methylene chloride, isopropyl alcohol, acetone, methanol, ethanol and water. Either or both of the sub coat layer and the enteric coat layer may be applied using a hot melt technique. In another general aspect there is provided a method of treating a patient for a condition for which a benzimidazole derivative is needed. The method includes administering a pharmaceutical composition of benzimidazole derivative that includes one or more cores containing an acid labile benzimidazole derivatives and at least 10% w/w of low- viscosity hydroxypropylcellulose by weight of the benzimidazole. Embodiments of the method of treating may include one or more of the following features or those described above. For example, the benzimidazole derivative may be selected from the group that includes esomeprazole, omeprazole, lansoprazole, leminoprazole, pariprazole, rabeprazole, pantoprazole; and their pharmaceutically acceptable salts. The acceptable salt may be one or more of sodium, potassium, calcium, and magnesium. The benzimidazole derivative may be one or both of pantoprazole sodium and rabeprazole sodium. The details of one or more embodiments of the inventions are set forth in the description below. Other features, objects and advantages of the inventions will be apparent from the description and claims. Detailed Description of the Invention As may be evident from the discussion of the background above, stabilization of benzimidazole derivatives in pharmaceutical compositions has been a key area of research ever since the discovery of these benzimidazoles as potent proton pump inhibitors. We have now discovered that degradation of benzimidazole derivatives, particularly pantoprazole and rabeprazole, in pharmaceutical compositions can be inhibited by the incorporation of a conventionally used binder, low- viscosity hydroxypropylcellulose, in amounts greater than used in the past as a binder in admixture with benzimidazole derivative. The term "benzimidazole derivative" as used herein includes benzimidazole derivatives that are used as proton pump inhibitors. Examples include esomeprazole, omeprazole, lansoprazole, leminoprazole, pariprazole, rabeprazole, pantoprazole; and pharmaceutically acceptable salts thereof. Pharmaceutically acceptable salts include metal salts of sodium, potassium, calcium, magnesium and the like. In particular pantoprazole sodium or rabeprazole sodium may be used. Low- iscosity hydroxypropylcellulose is conventionally used as a binder, although in low amounts. However, the pharmaceutical compositions of the present invention comprise increased or high amounts of low- viscosity hydroxypropylcellulose, at least in amounts greater than as a conventional binder. We have surprisingly discovered that the chemical degradation, as well as the discoloration, of highly acid- labile benzimidazole derivatives, particularly pantoprazole and rabeprazole, may be inhibited or at least reduced to a reasonable extent with the use of higher amounts of low- viscosity hydroxypropylcellulose. The amount of low- viscosity hydroxypropylcellulose should be at least about 10% by weight of the weight of benzimidazole derivative, and in particular from about 10% to about 100% of the weight of the benzimidazole derivative. As detailed below, pharmaceutical compositions comprising pantoprazole and higher amounts of low- viscosity hydroxypropylcellulose were prepared and evaluated for stability at 400°C and 75 % relative humidity over a period of 3 months. The results of the stability evaluation, listed in Table 1 below are highly convincing for recommending the use of low- viscosity hydroxypropylcellulose as a stabilizer. The results in Table 1 further reveal the synergistic improvement in stability upon incorporation of alkaline reacting compounds. Hydroxypropylcellulose is a non-ionic water-soluble cellulose ether that is formed by reaction with propylene oxide. It has a longstanding history of safe and effective use in the pharmaceutical industry. Hydroxypropylcellulose is commercially available from Aqualon and Nippon Soda Co. under the brand names Klucel® and HPC® and provides a remarkable set of physical properties for tablet binding, modified release, and film coating. Based on the requirement and the role it has to play in the pharmaceutical composition, hydroxypropylcellulose of a desired viscosity range may be selected. Broadly, the viscosity ranges and corresponding hydroxylpropylcelluloses are classified as low, medium and high viscosity hydroxypropylcelluloses. Examples of low-viscosity hydroxypropylcellulose include Klucel EF, Klucel LF, Klucel JF and Klucel GF, whose 2% by weight aqueous solutions have viscosities less than about 1000 cPs. Other examples are HPC-SL, HPC-L, and HPC-M whose 2% by weight aqueous solutions have viscosities of 3-6, 6-10, and 150-400 cPs, respectively. In particular HPC-L may be used. The term "pharmaceutical composition" as used herein includes solid dosage forms such as powder, tablet, granule, pellet, spheroid, capsule, and the like. The pharmaceutical composition may include one or more of a core, a sub coat layer, an enteric coat layer, and one or more pharmaceutically acceptable inert excipients. The term "core" as used herein includes conventionally used cores for oral administration such as tablets, granules, pellets, spheroids, capsules and the like. The core may comprise acid-labile benzimidazole derivative and low- viscosity hydroxypropylcellulose with or without other pharmaceutically acceptable inert excipients. The sub coat layer may comprise a film-forming agent with or without other pharmaceutically acceptable inert excipients. Specific examples of film forming agents include carageenan, hydroxypropyl methylcellulose, hydroxypropylcellulose, methylcellulose, carboxymethylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, polyethylene glycol, polyvinyl alcohol, xanthan gum and the like. In particular, hydroxypropylmethyl cellulose may be used as the film forming agent in concentrations from about 40% to about 90% by weight of the total solid content in the coating composition. Sub coating is carried out until a weight build-up is attained of about 7.5% to about 20% w/w over the core, in particular about 10% to about 20% w/w. The enteric coat layer may comprise an enteric polymer with or without other pharmaceutically acceptable inert excipients. Specific examples of enteric polymers include cellulose acetate phthalate, hydroxypropyl methylcellulose acetate phthalate, polyvinyl acetate phthalate, hydroxy propyl phthalate, hydroxypropyl methylcellulose phthalate (HPMC phthalate), hydroxypropyl methylcellulose acetate succinate; methacrylic acid copolymers such as Eudragit® L 100-55, Eudragit® L30 D-55, Eudragit® L 100, Eudragit® S 100; and mixtures thereof. In particular, methacrylic acid copolymers (type C), for example, Eudragit® L30 D-55 & Eudragit® L 100 maybe used as the enteric polymer in concentrations from about 40% to about 95% by weight of the total solid content in the coating composition. Enteric coating is carried out until attaining a weight build up of about 7.5% to about 15 % w/w over the sub coated core, in particular about 10% to about 12.5% w/w. The term "pharmaceutically acceptable inert excipients" as used herein includes all physiologically inert excipients used in the pharmaceutical art of dispensing. Examples include alkaline reacting compounds, antioxidants, binders, diluents, disintegrants, surfactants, plasticizers, lubricants/glidants, coloring agents, flavoring agents, and the like. Examples of alkaline reacting compound include sodium, potassium, calcium, magnesium, and aluminum salts of phosphoric acid, carbonic acid, citric acid or other suitable wealc inorganic or organic acids, such as sodium carbonate; substances normally used in antacid preparations such as aluminum, calcium and magnesium hydroxides; magnesium oxide or composite substances such as Al2O3.6MgO.Cθ2.12H2θ, (Mg6Al2(OH)ι6CO3.4H2O), MgO.Al2O3.2SiO2.nH2O or similar compounds; organic pH buffering substances such as trihydroxymethylaminomethane and the like. Examples of suitable antioxidants include lipophillic antioxidants, inorganic antioxidants and the like. In particular butylated hydroxy anisole (BHA) and butylated hydroxy toluene (BHT) alone or in combination may be used. Specific examples of binders include methyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, polyvinylpyrrolidone, gelatin, gum arabic, ethyl cellulose, polyvinyl alcohol, pullulan, pregelatinized starch, agar, tragacanth, sodium alginate, propylene glycol, and the like. Specific examples of diluents include calcium carbonate, calcium phosphate- dibasic, calcium phosphate-tribasic, calcium sulfate, cellulose-microcrystalline, cellulose powdered, dextrates, dextrins, dextrose excipients, fructose, kaolin, lactitol, lactose, mannitol, sofbitol, starch, starch pregelatinized, sucrose, sugar compressible, sugar confectioners, and the like. Specific examples of disintegrants include low-substituted hydroxypropylcellulose L-HPC), sodium starch glycollate, carboxymethyl cellulose, calcium carboxymethyl cellulose, sodium carboxymethyl cellulose, croscarmellose sodium A-type (Ac-di-sol), starch, crystalline cellulose, hydroxypropyl starch, partly pregelatinized starch, and the like. Examples of surfactants include both non-ionic and ionic (cationic, anionic and zwitterionic) surfactants suitable for use in pharmaceutical compositions. These include polyethoxylated fatty acids and their derivatives, for example polyethylene glycol 400 distearate, polyethylene glycol - 20 dioleate, polyethylene glycol 4 -150 mono dilaurate, polyethylene glycol -20 glyceryl stearate; alcohol - oil transesterification products, for example polyethylene glycol - 6 corn oil; polyglycerized fatty acids, for example polyglyceryl — 6 pentaoleate; propylene glycol fatty acid esters, for example propylene glycol monocaprylate; mono and diglycerides for example glyceryl ricinoleate; sterol and sterol derivatives; sorbitan fatty acid esters and its derivatives, for example polyethylene glycol - 20 sorbitan monooleate, sorbitan monolaurate; polyethylene glycol alkyl ether or phenols, for example polyethylene glycol - 20 cetyl ether, polyethylene glycol - 10 - 100 nonyl phenol; sugar esters, for example sucrose monopalmitate; polyoxyethylene - polyoxypropylene block copolymers known as "poloxamer"; ionic surfactants, for example sodium caproate, sodium glycocholate, soy lecithin, sodium stearyl fumarate, propylene glycol alginate, octyl sulfosuccinate disodium, palmitoyl carnitine; and the like Specific examples of lubricants/glidants include colloidal silicon dioxide, stearic acid, magnesium stearate, calcium stearate, zinc stearate, sodium stearyl fumarate, talc, hydrogenated castor oil, sucrose esters of fatty acid, microcrystalline wax, yellow beeswax, white beeswax, and the like Specific examples of plasticizers include acetylated triacetin, triethylcitrate, tributylcitrate, glyceroltributyrate, monoglyceride, rape oil, olive oil, sesame oil, acetyltributylcitrate, acetyltriethylcitrate, glycerin sorbitol, diethyloxalate, diethyl phthalate, diethyimalate, diethylfumarate, dibutylsuccinate, diethylmalonate, dioctylphthalate, dibutylsebacate, and the like. Coloring agents and flavoring agents include any FDA approved color or flavor for oral use. Stable pharmaceutical compositions of acid- labile benzimidazole derivative may be prepared by processes known in the prior art including, for example, by comminuting, mixing, granulation, melting, sizing, filling, drying, molding, immersing, coating, compressing, extrusion-spheronization etc. In a first embodiment, a core that includes an acid-labile benzimidazole derivative is prepared by a process that includes the steps of blending benzimidazole derivative and low-viscosity hydroxypropylcellulose with or without one or more pharmaceutically acceptable inert excipients; wet granulating the blend with a granulating fluid or solution/dispersion of one or more pharmaceutically acceptable inert excipients in the granulating fluid; drying and sizing the granules; optionally blending with one or more pharmaceutically acceptable inert excipient; and forming a suitable sized core. In a second embodiment, a core that includes an acid-labile benzimidazole derivative is prepared by a process that includes the steps of blending benzimidazole derivative and low-viscosity hydroxypropylcellulose with or without one or more pharmaceutically acceptable inert excipients; dry granulating the blend by roller compactor or slugging; sizing the granules; optionally blending with one or more pharmaceutically acceptable inert excipients; and forming a suitable sized core. In a third embodiment, a core that includes an acid-labile benzimidazole derivative is prepared by a process that includes the steps of blending benzimidazole derivative and low-viscosity hydroxypropylcellulose with or without one or more pharmaceutically acceptable inert excipients; and forming a suitable sized core. In a fourth embodiment, a core that includes an acid-labile benzimidazole derivative is prepared by a process that includes the steps of blending benzimidazole derivative and low- viscosity hydroxypropylcellulose with or without one or more pharmaceutically acceptable inert excipients; forming a wet mass using a granulating fluid or solution/dispersion of one or more pharmaceutically acceptable inert excipients in the granulating fluid; passing the wet mass through an extruder equipped with a screen; spheronizing the extrudate in a spheronizer; drying and sizing the spheroids; and forming a suitable sized core. The sub coat layer and enteric coat layer may be applied over the core prepared by any of the methods above in the form of a solution or dispersion of a film forming agent or an enteric polymer, with or without other pharmaceutically acceptable inert excipients. These coatings may be applied using any conventional coating technique known in the art, including spray coating in a conventional coating pan or fluidized bed processor, or dip coating. Alternatively, either of both of the coatings can be applied using a hot melt technique. Specific examples of solvents used as a granulating fluid and for preparing the solution/dispersion of coating substances include methylene chloride, isopropyl alcohol, acetone, methanol, ethanol, water and the like. The invention is further illustrated by the following examples, which are not intended and should not bee construed to limit the scope of the invention. Examples 1-7 Core tablets
Procedure: A portion of the mannitol, a portion of the microcrystalline cellulose, a portion of the disintegrant (crospovidone or sodium starch glyeollate or L-HPC, etc., respectively) and a portion of the low viscosity hydroxypropylcellulose were mixed with pantoprazole sodium in a high shear blender. This premix was granulated using purified water and the bulk then was dried. The dried granules were sized and mixed with extra granular excipients, which may include the remaining parts of mannitol, microcrystalline cellulose, disintegrant and low-viscosity hydroxypropylcellulose. The blend so obtained then was lubricated with calcium stearate and compressed into suitable sized tablets. The core tablets containing alkaline stabilizer were prepared by incorporating sodium carbonate intra granularly and/or extra granularly. Sub coat Layer
Ingredient Weight (%)
Hydroxypropyl methylcellulose 82.58
Povidone 3.33 Titanium dioxide 1.47
Ferric oxide yellow 0.05
Propylene glycol 2.79 Procedure: 1. Propylene glycol and povidone were dissolved in purified water to form a clear solution. 2. Appropriately sieved titanium dioxide and ferric oxide yellow were dispersed in purified water under constant stirring and passed through a colloid mill to form a dispersion. 3. The dispersion of step 2 was added to the solution of step 1. 4. Hydroxypropyl methylcellulose was added to the dispersion of step 3 under stirring for 30 minutes to give a uniform dispersion of 10 - 20 % w/w. 5. The core tablets prepared in the Example 1-7 above then were coated with the dispersion of step 4 until the desired weight build up was attained.
Enteric coat layer Ingredient Weight (%)
Eudragit L 30D 84.84
Triethyl citrate 9.07
Sodium lauryl sulphate 1.49
Titanium dioxide 4.47 Ferric oxide yellow 0.14 Procedure: 1. Appropriately sieved titanium dioxide and ferric oxide yellow were dispersed in purified water under constant stirring and passed through a colloid mill. 2. Sodium lauryl sulphate and triethyl citrate were added to the dispersion of step 1 under continuous stirring. 3. Eudragit L 30 D was dispersed in purified water under continuous stirring, to achieve a final dispersion of 10 - 25 % w/w. 4. The dispersion of step 2 was added to the dispersion of step 3 slowly, under continuous stirring, followed by continued stirring for at least one hour. 5. The sub coated tablets prepared above then were coated with the dispersion of step 4 until the desired weight build up was attained. The coated tablets were stored at 40 C and 75% relative humidity for 3 months and then the impurities were measured. The results are provided below in Table 1. The results in Table 1 demonstrate that the degradation of benzimidazole derivatives, particularly pantoprazole and rabeprazole, in pharmaceutical compositions can be inhibited by the incorporation of low-viscosity hydroxypropylcellulose at amounts greater than used in the past as a binder in admixture with benzimidazole derivative and therefore support the use of low- viscosity hydroxypropylcellulose as a stabilizer. Table 1. Stability data generated after storage of coated tablets at 40°C, 75% relative humidity for three months
While the present invention has been described in terms of its specific embodiments, certain modifications and equivalents will be apparent to those skilled in the art and are included within the scope of the present invention.

Claims

We Claim: 1. A pharmaceutical composition comprising one or more cores, the cores comprising: an acid-labile benzimidazole derivative; and at least 10% w/w of low-viscosity hydroxypropylcellulose by weight of the benzimidazole derivative.
2. The pharmaceutical composition according to claim 1 wherein the low-viscosity hydroxypropylcellulose may vary from about 10% to about 100% by weight of the weight of the benzimidazole derivative.
3. The pharmaceutical composition according to claim 1 wherein the low- viscosity hydroxypropylcellulose comprises a hydroxypropylcellulose having a viscosity less than about 1000 cps.
4. The pharmaceutical composition, according to claim 1 wherein the benzimidazole derivative comprises one or more selected from the group consisting of esomeprazole, omeprazole, lansoprazole, leminoprazole, pariprazole, rabeprazole, pantoprazole, and their pharmaceutically acceptable salts with metals.
5. The pharmaceutical composition according to claim 4 wherein the benzimidazole derivative comprises one or both of pantoprazole sodium and rabeprazole sodium.
6. The pharmaceutical composition according to claim 1 wherein the composition further comprises one or more pharmaceutically acceptable inert excipients.
7. The pharmaceutical composition according to claim 6 wherein the one or more pharmaceutically acceptable inert excipients are selected from the group consisting of alkaline reacting compounds, antioxidants, binders, diluents, disintegrants, surfactants, plasticizers, coloring agents and flavoring agents.
8. The pharmaceutical composition according to claim 1 wherein pharmaceutical composition comprises a solid dosage form selected from the group consisting of powder, tablet, granule, pellet, spheroid and capsule.
9. The pharmaceutical composition according to claim 1 further comprising one or both of a sub-coat layer and an enteric coat layer around the core.
10. The pharmaceutical composition according to claim 9 wherein the sub coat layer comprises one or more film-forming agents.
11. The pharmaceutical composition according to claim 10 wherein the film-forming agent is selected from the group consisting of carageenan, ethylcellulose, hydroxypropyl methylcellulose, hydroxypropyl cellulose, methylcellulose, carboxymethylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, polyethylene glycol, polyvinyl alcohol and xanthan gum.
12. The pharmaceutical composition according to claim 10 wherein the film-forming agent comprises hydroxypropyl methylcellulose.
13. The pharmaceutical composition according to claim 9 wherein the enteric coat layer comprises one or more enteric polymers.
14. The pharmaceutical composition according to claim 13 wherein the enteric polymer comprises one or more of cellulose acetate phthalate, hydroxypropyl methylcellulose acetate phthalate, polyvinyl acetate phthalate, hydroxy propyl phthalate, hydroxypropyl methylcellulose phthalate hydroxypropyl methylcellulose acetate succinate; and methacrylic acid copolymers.
15. The pharmaceutical composition according to claim 13 wherein the enteric polymer comprises methacrylic acid copolymer.
16. The pharmaceutical composition according to claim 7 wherein the alkaline reacting compound comprises one or more of sodium, potassium, calcium, magnesium, and aluminum salts of phosphoric acid, carbonic acid, citric acid or other weak inorganic or organic acids, aluminum hydroxides, calcium hydroxides and magnesium hydroxides, magnesium oxide, Al203.6Mg0.CO2.12H2O, (Mg6Al2(OH)16CO3.4H2O), MgO.Al2O3.2SiO2.riH2O, organic pH buffering substances, and trihydroxymethylaminomethane.
17. The pharmaceutical composition according to claim 16 wherein the alkaline reacting compound comprises sodium carbonate.
18. A process for the preparation of a pharmaceutical composition comprising one or more cores, the process comprising forming a core containing an acid-labile benzimidazole derivative and at least 10% w/w of low- viscosity hydroxypropylcellulose by weight of the benzimidazole derivative.
19. The process according to claim 18, wherein the acid-labile benzimidazole is blended with the low-viscosity hydroxypropylcellulose with or without one or more pharmaceutically acceptable inert excipients and then formed into the core.
20. The process according to claim 18, further comprising coating the core with one or both of a sub coat layer and an enteric coat layer.
21. The process according to claim 19 wherein the blend is granulated.
22. The process according to claim 21 wherein the granulation is carried out by wet granulation or dry granulation technique.
23. The process according to claim 21 wherein the blend is further processed into a suitable sized core by the process of extrusion-spheronization.
24. The process according to claim 20 wherein either or both of the sub coat layer and the enteric coat layer are applied as a solution or dispersion of film-forming agent or enteric polymer in a suitable solvent.
25. The process according to claim 24 wherein solvent is selected from the group consisting of methylene chloride, isopropyl alcohol, acetone, methanol, ethanol and water.
26. The process according to claim 20 wherein either or both of the sub coat layer and the enteric coat layer are applied using a hot melt technique.
27. The process according to claim 18 further comprising forming the cores into tablets.
28. A method of treating a patient for a condition for which a benzimidazole derivative is needed, the method comprising administering a pharmaceutical composition of benzimidazole derivative comprising one or more cores containing an acid labile benzimidazole derivatives and at least 10% w/w of low- viscosity hydroxypropylcellulose by weight of the benzimidazole.
29. The method according to claim 28 wherein the benzimidazole derivative is selected from the group consisting of esomeprazole, omeprazole, lansoprazole, leminoprazole, pariprazole, rabeprazole, pantoprazole; and their pharmaceutically acceptable salts.
30. The method according to claim 29, wherein the acceptable salt comprises one or more of sodium, potassium, calcium, and magnesium.
31. The method according to claim 28 wherein the benzimidazole derivative comprises one or both of pantoprazole sodium and rabeprazole sodium.
EP04769201A 2003-08-28 2004-08-27 Pharmaceutical compositions of benzimidazole and processes for their preparation Withdrawn EP1696889A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN1047DE2003 2003-08-28
PCT/IB2004/000536 WO2004075881A1 (en) 2003-02-28 2004-03-01 Stable pharmaceutical composition of rabeprazole and processes for their preparation
PCT/IB2004/002784 WO2005027876A1 (en) 2003-08-28 2004-08-27 Pharmaceutical compositions of benzimidazole and processes for their preparation

Publications (1)

Publication Number Publication Date
EP1696889A1 true EP1696889A1 (en) 2006-09-06

Family

ID=36791047

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04769201A Withdrawn EP1696889A1 (en) 2003-08-28 2004-08-27 Pharmaceutical compositions of benzimidazole and processes for their preparation

Country Status (2)

Country Link
EP (1) EP1696889A1 (en)
WO (1) WO2005027876A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105878203A (en) * 2016-06-23 2016-08-24 南京华宽信息咨询中心 Lansoprazole enteric-coated tablet for treating gastric ulcer and preparation method thereof

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9720061D0 (en) 1997-09-19 1997-11-19 Crosfield Joseph & Sons Metal compounds as phosphate binders
GB0502787D0 (en) * 2005-02-10 2005-03-16 Ineos Silicas Ltd Pharmaceuticlly active compounds, their manufacture, compositions containing them and their use
EP1895990A2 (en) * 2005-05-13 2008-03-12 Combino Pharm, S.L. Formulations containing pantoprazole free acid and its salts
MY157620A (en) 2006-01-31 2016-06-30 Cytochroma Dev Inc A granular material of a solid water-soluble mixed metal compound capable of binding phosphate
EP1872778A1 (en) * 2006-06-29 2008-01-02 LEK Pharmaceuticals D.D. Stable pharmaceutical composition with rabeprazole sodium
GB0714670D0 (en) 2007-07-27 2007-09-05 Ineos Healthcare Ltd Use
GB0720220D0 (en) 2007-10-16 2007-11-28 Ineos Healthcare Ltd Compound
GB0913525D0 (en) 2009-08-03 2009-09-16 Ineos Healthcare Ltd Method
GB201001779D0 (en) 2010-02-04 2010-03-24 Ineos Healthcare Ltd Composition
WO2011102504A1 (en) * 2010-02-22 2011-08-25 第一三共株式会社 Sustained-release solid preparation for oral use
EP2647648B1 (en) * 2010-12-03 2017-08-09 Nippon Soda Co., Ltd. Solid dosage form containing a low viscosity HYDROXYALKYL CELLULOSE
CN104352481A (en) * 2014-11-06 2015-02-18 成都医路康医学技术服务有限公司 Preparation method of esomeprazole magnesium slow-release enteric micro capsule
CN109806215B (en) * 2019-04-10 2021-09-28 湖南素元生物科技有限公司 Gastrodia elata mask emulsion and ultrasonic preparation method thereof
CN113125583B (en) * 2019-12-30 2022-06-21 成都百裕制药股份有限公司 A kind of detection method of genotoxic impurity content in pantoprazole sodium for injection

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2145102T3 (en) * 1993-09-09 2000-07-01 Takeda Chemical Industries Ltd FORMULATION COMPRISING AN ANTIBACTERIAL SUBSTANCE AND AN ANTI-ULCER SUBSTANCE.
GB9710800D0 (en) * 1997-05-23 1997-07-23 Cipla Limited Pharmaceutical composition and method of preparing it
WO1999059544A2 (en) * 1998-05-18 1999-11-25 Takeda Chemical Industries, Ltd. Orally disintegrable tablets
KR100314351B1 (en) * 1998-10-01 2002-03-21 민경윤 Enteric preparation of benzimidazole derivatives and preparation method thereof
SE9902386D0 (en) * 1999-06-22 1999-06-22 Astra Ab New formulation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2005027876A1 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105878203A (en) * 2016-06-23 2016-08-24 南京华宽信息咨询中心 Lansoprazole enteric-coated tablet for treating gastric ulcer and preparation method thereof

Also Published As

Publication number Publication date
WO2005027876A1 (en) 2005-03-31

Similar Documents

Publication Publication Date Title
JP4638561B2 (en) Multiple unit boiling dosage forms containing proton pump inhibitors
AU767289B2 (en) Omeprazole formulation
US7029701B2 (en) Composition for the treatment and prevention of ischemic events
AU2004278037B2 (en) Pantoprazole multiparticulate formulations
US20090068263A1 (en) Multiple unit compositions
JPH09511767A (en) Novel oral pharmaceutical use form
EP1233768A1 (en) Carvedilol methanesulfonate
JP2002532425A (en) New pharmaceutical formulations
JP2001526213A (en) Oral drug pulse release dosage form
EP2793866B2 (en) Bilayer tablet comprising benazepril hydrochloride and pimobendan
US20080003281A1 (en) Modified Release Tablet Formulations for Proton Pump Inhibitors
WO2005027876A1 (en) Pharmaceutical compositions of benzimidazole and processes for their preparation
WO2011140446A2 (en) Pharmaceutical formulations
EP3646855B1 (en) Oral solid preparation composition comprising proton pump inhibitor, oral solid preparation comprising same, and preparation method therefor
US20080095853A1 (en) Modified Release For Proton Pump Inhibitors
JP4705747B2 (en) Pharmaceutical composition
EP2345408A2 (en) Acid labile drug formulations
MX2008016565A (en) Pharmaceutical compositions comprising a combination of piperidinoalkanol and decongestant.
EP1930030A1 (en) Pulse preparation having improved disintegration properties in vivo
WO2013181292A1 (en) Nitisinone formulations
WO2004066982A1 (en) Stable oral benzimidazole compositions and processes for their preparation
US20240033224A1 (en) Enteric-coated pellet, method for preparing same and formulation comprising same
CN100431526C (en) A rapidly disintegrating tablet for an acid-sensitive drug
CA2547398A1 (en) Oral benzimidazole compositions comprising an active core, an optional separating layer and an enteric coating
WO2004075881A1 (en) Stable pharmaceutical composition of rabeprazole and processes for their preparation

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060718

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
RIN1 Information on inventor provided before grant (corrected)

Inventor name: KUMAR, PANANCHUKUNNATH, MANOJ

Inventor name: SETHI, SANJEEV, KUMAR

Inventor name: SINGH, ROMI, BARAT

Inventor name: NAGAPRASAD, VISHNUBHOTLA

Inventor name: MALIK, RAJIV

17Q First examination report despatched

Effective date: 20080214

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080303